SCCS Revision of the Scientific Opinion on Vitamin A
Ingredients: RETINOL, RETINYL PALMITATE, RETINYL ACETATE, RETINYL LINOLEATE, RETINAL

Date of publication: 25/10/2022

The Scientific Committee on Consumer Safety has issued a final version of the Scientific Opinion on Vitamin A, concluding that exposure to Vitamin A derived from cosmetics can be a concern for higher exposure consumers, and since cosmetics alone do not exceed the upper limit the SCCS cannot suggest maximum concentration limits that take into account contributions from other sources.

BACKGROUND

Vitamin A is a group of lipid-soluble compounds that includes Retinol, Retinyl Palmitate, Retinyl Acetate, Retinyl Linoleate and Retinal. This vitamin is an essential micronutrient for most mammalian species, taking part in vision, immunity and embryo development, among others. Retinol (CAS number: 68-26-8 /11103-57-4), Retinyl Palmitate (CAS number: 79-81-2) and Retinyl Acetate (1CAS number: 27-47-9) are used as skin conditioning agents in cosmetics and personal care products.

In 2016, the European Commission’s Scientific Committee on Consumer Safety (SCCS) issued an opinion on Vitamin A (Retinol, Retinyl Acetate, Retinyl Palmitate). The teratogenic potential of Vitamin A and effects on liver and skin were considered the most critical toxicological endpoints. The SCCS concluded that Vitamin A (Retinol, Retinyl Acetate, Retinyl Palmitate) at a maximum concentration of 0.05% (of retinol equivalent, RE) in body lotions is per se safe. The SCCS also considered that Vitamin A (Retinol, Retinyl Acetate, Retinyl Palmitate) at a maximum concentration of 0.3% RE for example in hand cream, face cream and leave-on and rinse-off products per se is safe. Simultaneously, baby skin care products, like body lotions and creams, containing Vitamin A (Retinol, Retinyl Acetate, Retinyl Palmitate) were considered safe for 1–3-year-old children. However, the cumulative exposure to Vitamin A (Retinol, Retinyl Acetate, Retinyl Palmitate) from sunscreen products, derivatives of Retinyl Linoleate and Retinal, exposure from sources other than cosmetic products, were not included in the SCCS opinion. Yet, the SCCS recognized that population’s overall exposure to Vitamin A (Retinol, Retinyl Acetate, Retinyl Palmitate) can be significantly higher, especially because the most important source of Vitamin A is usually diet (followed by supplements and cosmetics).

WHAT’S NEW?

After novel toxicological data regarding aggregated exposure to Vitamin A from cosmetics, diet and supplementation, and the contribution of cosmetic Vitamin A to the overall exposure to Vitamin A, the SCCS issued a revision of the opinion on October 2022. The SCCS concluded the following:

  • Regarding the contribution of cosmetic products to the overall/total exposure to Vitamin A, the SCCS considers that there are inconsistencies in model calculations. The probabilistic assessment regarding the contribution from food and food supplements shows that the exposure to Vitamin A of the most exposed consumers (5% of the total population) may already exceed the upper limit. Compared to food, the contribution of Vitamin A from cosmetics is lower. However, this can be a concern for consumers with highest exposure (5% of the total population) to vitamin A derived already derived from food and food supplements.
  • Regarding the updating of the maximum concentration limit for the different categories of cosmetic ingredients, the SCCS considers that cosmetics alone do not exceed the upper limit imposed for exposure to Vitamin A and contribution of different exposure sources is a risk management issue and cannot be addressed at the level of risk assessment. In this way, the SCCS cannot suggest maximum concentration limits that take into account contributions from other sources like food and food supplements.

References:

1. SCCS (Scientific Committee on Consumer Safety), revision of the scientific Opinion (SCCS/1576/16) on vitamin A (Retinol, Retinyl Acetate, Retinyl Palmitate), preliminary version of 10 December 2021, final version of 24-25 October 2022, SCCS/1639/21.

further
reading

cosmetic products

Citral under review: SCCS Preliminary Opinion

The SCCS was tasked by the European Commission to evaluate if the safety levels for Citral, determined through QRA2 based on skin sensitization induction, are sufficient to safeguard consumers. A preliminary opinion was released.

Read More »
cosmetic products

Are sunscreens with Benzophenone-4 safe?

Benzophenone-4 is commonly known as a UV-filter in cosmetic products. Learn what the final opinion of SCCS states about Benzophenone’s safety profile as a UV-filter in cosmetic products.

Read More »
cosmetic products

Is Aluminium in cosmetics safe for human health?

The Scientific Committee on Consumer Safety (SCCS) published its Final Opinion on the safety of Aluminium in cosmetic products. This follows a lengthy review process that began in 2013 when the SCCS was first mandated to evaluate the potential health risks of Aluminium (Al) and its compounds in cosmetics.

Read More »
cosmetic products

Silver in Cosmetics: SCCS preliminary opinion.

Ingredients: SILVER

The recent preliminary opinion from the Scientific Committee on Consumer Safety (SCCS) regarding silver in cosmetics is crucial for consumers and manufacturers. This article breaks down the key points, making it easier to understand the implications and stay informed.

Read More »
news & updates

EU Ecolabel adoption and recognition are on the rise

The Ecolabel certification is a comprehensive program focused on fostering sustainable practices. It evaluates products based on life cycle assessments, where every phase of said life cycle must abide by strict standards to attain the Ecolabel certification. The overarching objective of this certification is minimizing environmental harm from production or consumption activities.

Read More »
cosmetic products

UK proposes ban of wet wipes containing plastic 

The UK has proposed, on April 24, 2024, a regulation titled The Environmental Protection (Wet Wipes Containing Plastic) (England) Regulations 2024, to the World Trade Organization (WTO). The regulation aims to eliminate the supply and sale of plastic-containing wet wipes, including cosmetic ones. The public can offer comments on the draft until June 23, 2024, with adoption expected in September of the same year.

Read More »
news & updates

SCCS preliminary opinion on Citral sensitization endpoint

Ingredients: CITRAL

Date of publication: 27/03/2024

On March 27 2024, the Scientific Committee on Consumer Safety (SCCS) published the Preliminary Opinion on the safety of Citral in cosmetic products. The deadline for comments is set to June 2, 2024.

Read More »
medical devices

Safety Reporting in Clinical Investigations: a Gap Analysis of Guidance Documents 

Safety reporting in clinical investigations of medical devices shall be performed in line with Article 80(2) of the EU MDR. On May 2020, it was published the MDCG 2020-10/1, outlining the procedures for safety reporting in clinical investigations of medical devices under the EU MDR. However, on October 2022 the Medical Device Coordination Group (MDCG) published an updated version of the MDCG 2020-10/1, the MDCG 2020-10/1 Rev 1. This article highlights the updates included in the new revision, analysing the gaps between both documents.

Read More »
medical devices

Roles and Responsibilities of an Authorised Representative under EU MDR and IVDR 

If a medical device manufacturer is not established in a Member State, the devices can only be placed on the Union market if the manufacturer designates an authorised representative. The authorised representative plays a pivotal role in ensuring the compliance of the devices with EU regulation, serving as point of contact. The obligations and responsibilities of authorised representative are outlined on Article 11 of both MDR and IVDR, but clarification of relevant requirements is described in MDCG 2022-16 of October 2022.

Read More »
medical devices

Understanding the ISO Standards Lifecycle

ISO Standards cover a huge range of activities, representing the distilled wisdom of people with expertise in their subject matter and providing the regulators with a sound basis to develop better legislation. ISO Standards are diverse, addressing from the shoe size we wear to the quality of air we breathe. The medical device sector is no exception. ISO has many International Standards and guidance documents aimed at helping the sector ensure safe and effective medical devices while meeting the multitude of national, regional and international regulatory requirements. But how exactly is a Standard developed, reviewed and withdraw?

Read More »